Interim report Period from January 2022 to March 2022
Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED) GROUP 2022 FIRST QUARTER (Jan-Mar) · Net sales of products KSEK 8,908 (11,381) · Net sales adjusted excl. China 8,908 (9,181) KSEK · Gross profit KSEK 5,596 (6,568), Gross margin 63% (58%) · Operating loss KSEK -10,875 (-6,424) · Loss per share SEK -0.06 (-0.03)From the CEO Sales during the first quarter grew by + 58% compared with the previous quarter. In comparable figures (ex China) with the corresponding period last year, sales fell by -3%. An important underlying reason is